- Home
- News
- Articles+
- Aerospace
- Agriculture
- Alternate Dispute Resolution
- Banking and Finance
- Bankruptcy
- Book Review
- Bribery & Corruption
- Commercial Litigation
- Competition Law
- Conference Reports
- Consumer Products
- Contract
- Corporate Governance
- Corporate Law
- Covid-19
- Cryptocurrency
- Cybersecurity
- Data Protection
- Defence
- Digital Economy
- E-commerce
- Employment Law
- Energy and Natural Resources
- Entertainment and Sports Law
- Environmental Law
- FDI
- Food and Beverage
- Health Care
- IBC Diaries
- Insurance Law
- Intellectual Property
- International Law
- Know the Law
- Labour Laws
- Litigation
- Litigation Funding
- Manufacturing
- Mergers & Acquisitions
- NFTs
- Privacy
- Private Equity
- Project Finance
- Real Estate
- Risk and Compliance
- Technology Media and Telecom
- Tributes
- Zoom In
- Take On Board
- In Focus
- Law & Policy and Regulation
- IP & Tech Era
- Viewpoint
- Arbitration & Mediation
- Tax
- Student Corner
- AI
- ESG
- Gaming
- Inclusion & Diversity
- Law Firms
- In-House
- Rankings
- E-Magazine
- Legal Era TV
- Events
- News
- Articles
- Aerospace
- Agriculture
- Alternate Dispute Resolution
- Banking and Finance
- Bankruptcy
- Book Review
- Bribery & Corruption
- Commercial Litigation
- Competition Law
- Conference Reports
- Consumer Products
- Contract
- Corporate Governance
- Corporate Law
- Covid-19
- Cryptocurrency
- Cybersecurity
- Data Protection
- Defence
- Digital Economy
- E-commerce
- Employment Law
- Energy and Natural Resources
- Entertainment and Sports Law
- Environmental Law
- FDI
- Food and Beverage
- Health Care
- IBC Diaries
- Insurance Law
- Intellectual Property
- International Law
- Know the Law
- Labour Laws
- Litigation
- Litigation Funding
- Manufacturing
- Mergers & Acquisitions
- NFTs
- Privacy
- Private Equity
- Project Finance
- Real Estate
- Risk and Compliance
- Technology Media and Telecom
- Tributes
- Zoom In
- Take On Board
- In Focus
- Law & Policy and Regulation
- IP & Tech Era
- Viewpoint
- Arbitration & Mediation
- Tax
- Student Corner
- AI
- ESG
- Gaming
- Inclusion & Diversity
- Law Firms
- In-House
- Rankings
- E-Magazine
- Legal Era TV
- Events
PepGen Strengthens Legal Team with Mary Beth DeLena as General Counsel and Secretary
PepGen Strengthens Legal Team with Mary Beth DeLena as General Counsel and Secretary
On January 17, 2024, PepGen Inc., a company listed on Nasdaq under the ticker symbol PEPG, disclosed the appointment of Mary Beth DeLena as General Counsel and Secretary.
Bringing to PepGen over two decades of expertise, DeLena has joined the company with a wealth of experience advising global life science firms. Her extensive background spans a diverse range of strategic, transactional, and corporate matters, showcasing proficiency in areas such as business development, finance, securities, corporate governance, employment, and commercial law.
Before joining PepGen, DeLena spent 15 years at Alnylam Pharmaceuticals, progressing through roles of escalating responsibility. Her latest position at Alnylam was as Senior Vice President, Deputy General Counsel, and Assistant Secretary. Throughout her tenure, DeLena played a pivotal role in advising on transformative strategic collaborations, licensing transactions, and substantial capital-raising initiatives. Prior to her time at Alnylam, she played a key role at Praecis Pharmaceuticals, where she established and oversaw the corporate legal function.
DeLena initiated her career as an associate in the Boston office of Skadden, Arps, Slate, Meagher & Flom LLP. She holds a Juris Doctor from Northeastern University School of Law and earned her Bachelor of Arts in English from Trinity College.
“We are excited to welcome Mary Beth to the team and look forward to leveraging her extensive legal and compliance experience advising public life science companies,” James McArthur, Ph.D., President and CEO of PepGen said.
"I am excited to join the stellar team at PepGen and look forward to supporting the advancement of potentially transformative treatments to improve the future for patients with devastating neuromuscular and neurological diseases," DeLena said in a LinkedIn post.